Beovu beats Eylea in diabetic macular edema, Novartis says

14 September 2020
eye-big

Swiss pharma giant Novartis (NOVN: VX) has reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu (brolucizumab) 6 mg in diabetic macular edema (DME).

The trial met its primary and key secondary endpoints, demonstrating non-inferiority for Beovu versus aflibercept 2mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52).

Aflibercept is marketed by Regeneron (Nasdaq: REGN) and Bayer (BAYN: DE) under the brand name Eylea.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology